InvestorsHub Logo
Followers 32
Posts 3389
Boards Moderated 0
Alias Born 08/04/2009

Re: None

Monday, 08/17/2020 10:47:35 AM

Monday, August 17, 2020 10:47:35 AM

Post# of 27552
IBio Inc. (NYSEAMERICAN: IBIO) Announces Immune Response in Preclinical Studies of the IBIO-201 COVID-19 Vaccine Program
https://biopharmajournal.com/2020/08/17/ibio-inc-nyseamerican-ibio-announces-immune-response-in-preclinical-studies-of-the-ibio-201-covid-19-vaccine-program/

Tom Isett, CEO of iBio, Interview w/the Hill Talking About Meeting with BARDA


Company Overview
iBio, Inc. (NYSE MKT: IBIO), a leader in the plant-made pharmaceutical field, develops and offers pharmaceutical product applications using its iBio Technology platform.
The iBio Technology platform is a proprietary, transformative technology for the production of biologics including monoclonal antibodies, other therapeutic proteins and vaccines.

#iBio $iBio iBio
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IBIO News